Golden Biotechnology Corporation (TPEX: 4132)

Market Cap	2.73B
Revenue (ttm)	57.49M
Net Income (ttm)	-379.32M
Shares Out	162.23M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,208
Average Volume	436,619
Open	17.60
Previous Close	17.60
Day's Range	17.10 - 17.70
52-Week Range	14.85 - 43.15
Beta	1.05
RSI	51.75
Earnings Date	Apr 28, 2025

About Golden Biotechnology

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 122
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4132

Financial Performance

In 2023, Golden Biotechnology's revenue was 63.43 million, a decrease of -70.88% compared to the previous year's 217.83 million. Losses were -361.64 million, 33.0% more than in 2022.